Biotech Values

[pcrutch]

I'd agree with Dew on this point as well. Waiting to push development once final guidance has been given would put them at a significant disadvantage.

Others would continue development with the rough guidelines and be much further ahead in the regulatory process than Momenta. Falling behind really isn't an option.

They should be pushing the programs they can conduct now, without incurring undue regulatory risk.